|
US4107288A
(en)
|
1974-09-18 |
1978-08-15 |
Pharmaceutical Society Of Victoria |
Injectable compositions, nanoparticles useful therein, and process of manufacturing same
|
|
GB2160201B
(en)
|
1984-06-14 |
1988-05-11 |
Wyeth John & Brother Ltd |
Quinazoline and cinnoline derivatives
|
|
JPS646261A
(en)
|
1987-03-31 |
1989-01-10 |
Nisshin Flour Milling Co |
4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5034393A
(en)
|
1989-07-27 |
1991-07-23 |
Dowelanco |
Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
|
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
US5238951A
(en)
|
1991-02-01 |
1993-08-24 |
E. R. Squibb & Sons, Inc. |
Heterocyclic amido prostaglandin analogs
|
|
US5480883A
(en)
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
US6498144B1
(en)
|
1993-10-18 |
2002-12-24 |
North Shore - Long Island Jewish Research Institute |
Use of scatter factor to enhance angiogenesis
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
|
TW321649B
(enExample)
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
|
CA2223081C
(en)
|
1995-06-07 |
2001-03-06 |
Pfizer Inc. |
Heterocyclic ring-fused pyrimidine derivatives
|
|
AU5984296A
(en)
|
1995-06-07 |
1996-12-30 |
Sugen, Inc. |
Quinazolines and pharmaceutical compositions
|
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
|
EP0860433B1
(en)
|
1995-11-07 |
2002-07-03 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
|
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
GB9526546D0
(en)
|
1995-12-23 |
1996-02-28 |
Pfizer Ltd |
Compounds useful in therapy
|
|
IL125686A
(en)
|
1996-02-13 |
2002-11-10 |
Zeneca Ltd |
Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
IL125954A
(en)
|
1996-03-05 |
2003-06-24 |
Zeneca Ltd |
Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
|
|
WO1997034876A1
(en)
|
1996-03-15 |
1997-09-25 |
Zeneca Limited |
Cinnoline derivatives and use as medicine
|
|
US6107300A
(en)
|
1996-03-27 |
2000-08-22 |
Dupont Pharmaceuticals |
Arylamino fused pyrimidines
|
|
CN1923818A
(zh)
|
1996-04-12 |
2007-03-07 |
沃尼尔·朗伯公司 |
酪氨酸激酶的不可逆抑制剂
|
|
ATE227283T1
(de)
|
1996-07-13 |
2002-11-15 |
Glaxo Group Ltd |
Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
AU733551B2
(en)
|
1996-09-25 |
2001-05-17 |
Astrazeneca Ab |
Qinoline derivatives inhibiting the effect of growth factors such as VEGF
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
DK0882717T3
(da)
|
1996-10-01 |
2010-12-13 |
Kyowa Hakko Kirin Co Ltd |
Nitrogenholdige heterocykliske forbindelser
|
|
GB9700504D0
(en)
|
1997-01-11 |
1997-02-26 |
Pfizer Ltd |
Pharmaceutical compounds
|
|
GB9705361D0
(en)
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
EP0990647B1
(en)
|
1997-04-18 |
2003-07-02 |
Kirin Beer Kabushiki Kaisha |
Process for producing quinolone derivatives
|
|
EP0977737B1
(en)
|
1997-04-22 |
2003-09-17 |
Janssen Pharmaceutica N.V. |
Crf antagonistic quino- and quinazolines
|
|
GB9708917D0
(en)
|
1997-05-01 |
1997-06-25 |
Pfizer Ltd |
Compounds useful in therapy
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
DE69838172T2
(de)
|
1997-08-22 |
2008-04-10 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
JP2002516823A
(ja)
|
1998-05-28 |
2002-06-11 |
パーカー ヒューズ インスティテュート |
脳腫瘍の治療のためのキナゾリン
|
|
DE69942097D1
(de)
|
1998-08-11 |
2010-04-15 |
Novartis Ag |
Isochinoline derivate mit angiogenesis-hemmender wirkung
|
|
DE69924500T2
(de)
|
1998-08-21 |
2006-02-09 |
Parker Hughes Institute, St. Paul |
Chinazolinderivate
|
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
|
DE59911740D1
(de)
|
1998-09-10 |
2005-04-14 |
Bioequal Ag Muttenz |
Topisch anwendbare mittel gegen nagelpilzerkrankungen
|
|
ES2211175T3
(es)
|
1998-09-29 |
2004-07-01 |
Wyeth Holdings Corporation |
Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
|
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
PT1117653E
(pt)
|
1998-10-01 |
2003-06-30 |
Astrazeneca Ab |
Derivados de quinolina e quinazolina e sua utilizacao como inibidores de doencas mediadas pela citosina
|
|
CA2344290C
(en)
|
1998-10-08 |
2009-06-02 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
BR9915487A
(pt)
|
1998-11-19 |
2001-07-31 |
Warner Lambert Co |
N-[4-(3-cloro-4-flúor-fenilamino) - 7 - (3-morfolin-4-il-propóxi)-quinazolin-6-il]-acrilamida, um inibidor irreversìvel de tirosina quinases
|
|
ES2208261T3
(es)
|
1999-01-22 |
2004-06-16 |
Kirin Beer Kabushiki Kaisha |
Derivados de quinolina y derivados de quinazolina.
|
|
EE05708B1
(et)
|
1999-02-10 |
2014-04-15 |
Astrazeneca Ab |
Kinasoliini derivaat angiogeneesi inhibiitorina ja selle kasutamine
|
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
|
US6080747A
(en)
|
1999-03-05 |
2000-06-27 |
Hughes Institute |
JAK-3 inhibitors for treating allergic disorders
|
|
DE19911509A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6258820B1
(en)
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
|
AU3630100A
(en)
|
1999-03-19 |
2000-10-09 |
Parker Hughes Institute |
Quinazoline formulations and therapeutic use thereof
|
|
RS49836B
(sr)
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
|
GB9910577D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
US6126917A
(en)
|
1999-06-01 |
2000-10-03 |
Hadasit Medical Research Services And Development Ltd. |
Epidermal growth factor receptor binding compounds for positron emission tomography
|
|
EE04748B1
(et)
|
1999-06-21 |
2006-12-15 |
Boehringer Ingelheim Pharma Kg |
Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
|
|
GB9922171D0
(en)
|
1999-09-21 |
1999-11-17 |
Zeneca Ltd |
Chemical compounds
|
|
RU2002110461A
(ru)
|
1999-09-21 |
2004-03-10 |
Астразенека Аб (Se) |
Производные хиназолина и их применение в качестве фармацевтических веществ
|
|
US6759410B1
(en)
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
|
AU4903201A
(en)
|
1999-11-30 |
2001-07-03 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
|
US20020002169A1
(en)
|
1999-12-08 |
2002-01-03 |
Griffin John H. |
Protein kinase inhibitors
|
|
EP1243582A4
(en)
|
1999-12-24 |
2003-06-04 |
Kirin Brewery |
CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
|
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
EP1294709A2
(en)
|
2000-01-28 |
2003-03-26 |
AstraZeneca AB |
Quinoline derivatives and their use as aurora 2 kinase inhibitors
|
|
US6664390B2
(en)
|
2000-02-02 |
2003-12-16 |
Warner-Lambert Company Llc |
Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
|
|
AU2001236698A1
(en)
|
2000-02-07 |
2001-08-14 |
Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft |
2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
|
|
HK1048775B
(en)
|
2000-03-13 |
2006-01-20 |
Wyeth Holdings Corporation |
Use of cyanoquinolines for treating or inhibiting colonic polyps
|
|
US6608048B2
(en)
|
2000-03-28 |
2003-08-19 |
Wyeth Holdings |
Tricyclic protein kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
US6627634B2
(en)
|
2000-04-08 |
2003-09-30 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
EP1292591B1
(en)
|
2000-06-22 |
2005-02-02 |
Pfizer Products Inc. |
Substituted bicyclic derivatives for the treatment of abnormal cell growth
|
|
WO2002000649A1
(en)
|
2000-06-28 |
2002-01-03 |
Astrazeneca Ab |
Substituted quinazoline derivatives and their use as inhibitors
|
|
EP1174118A1
(de)
|
2000-06-28 |
2002-01-23 |
Cognis France S.A. |
Verwendung von Inulinen und Inulinderivaten
|
|
FR2811658B1
(fr)
|
2000-07-17 |
2004-07-02 |
Cfpi Nufarm |
Reacteur biologique a lit fixe immerge et procede de traitement d'effluents liquides
|
|
CA2417500C
(en)
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Erbb-2 selective small molecule kinase inhibitors
|
|
JP2004506732A
(ja)
|
2000-08-21 |
2004-03-04 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
US6653305B2
(en)
|
2000-08-26 |
2003-11-25 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
|
DE10042058A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
AU2001292137A1
(en)
|
2000-10-13 |
2002-04-22 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
WO2002030924A1
(en)
|
2000-10-13 |
2002-04-18 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
|
CN1308310C
(zh)
|
2000-10-20 |
2007-04-04 |
卫材R&D管理有限公司 |
含氮芳环衍生物
|
|
US20040063733A1
(en)
|
2000-10-25 |
2004-04-01 |
Lambert Christine Marie Paul |
Quinazoline derivatives
|
|
AU2002210714A1
(en)
|
2000-11-02 |
2002-06-11 |
Astrazeneca Ab |
Substituted quinolines as antitumor agents
|
|
JP2004517059A
(ja)
|
2000-11-02 |
2004-06-10 |
アストラゼネカ アクチボラグ |
抗腫瘍剤用の４−置換キノリン類
|
|
EP1340748B1
(en)
|
2000-11-02 |
2008-01-16 |
Nippon Shinyaku Co., Ltd. |
Quinazoline derivatives and drugs
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
US6900220B2
(en)
|
2001-01-02 |
2005-05-31 |
Syntex (U.S.A.) Llc |
Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
|
|
JP4307843B2
(ja)
|
2001-04-19 |
2009-08-05 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
|
CA2445333C
(en)
|
2001-04-27 |
2011-03-22 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives having azolyl group
|
|
SE0101675D0
(sv)
|
2001-05-11 |
2001-05-11 |
Astrazeneca Ab |
Novel composition
|
|
WO2002092579A1
(en)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
4-anilinoquinazoline derivatives
|
|
WO2002092577A1
(en)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
WO2002092578A1
(en)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US6734303B2
(en)
|
2001-05-18 |
2004-05-11 |
Pfizer Inc. |
Process for the production of quinazolines
|
|
DE10125432A1
(de)
|
2001-05-25 |
2002-11-28 |
Bayer Ag |
Substituierte Benzoylketone
|
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
|
KR100883731B1
(ko)
|
2001-06-22 |
2009-02-12 |
기린 파마 가부시끼가이샤 |
간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
|
|
KR100397792B1
(ko)
|
2001-06-28 |
2003-09-13 |
한국과학기술연구원 |
4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
|
|
GB0118752D0
(en)
|
2001-08-01 |
2001-09-26 |
Pfizer Ltd |
Process for the production of quinazolines
|
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
|
US20030066060A1
(en)
|
2001-09-28 |
2003-04-03 |
Ford Richard L. |
Cross profile guided optimization of program execution
|
|
US7495104B2
(en)
|
2001-10-17 |
2009-02-24 |
Kirin Beer Kabushiki Kaisha |
Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
GB0126433D0
(en)
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
|
GB0128108D0
(en)
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
|
UA77469C2
(en)
|
2001-11-27 |
2006-12-15 |
White Holdings Corp |
3-cyanoquinolines as egf-r and her2 kinase inhibitors
|
|
AU2002347336A1
(en)
|
2001-12-05 |
2003-06-17 |
Astrazeneca Ab |
Quinoline derivatives
|
|
GB0129099D0
(en)
|
2001-12-05 |
2002-01-23 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2002347359A1
(en)
|
2001-12-05 |
2003-06-17 |
Astrazeneca Ab |
Quinoline derivatives
|
|
EA200400680A1
(ru)
|
2001-12-12 |
2005-06-30 |
Пфайзер Продактс Инк. |
Производные хиназолина для лечения аномального роста клеток
|
|
AP2004003059A0
(en)
|
2001-12-12 |
2004-06-30 |
Pfizer Prod Inc |
Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
|
|
TW200301123A
(en)
|
2001-12-21 |
2003-07-01 |
Astrazeneca Uk Ltd |
New use
|
|
WO2003055866A1
(en)
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
|
US7402585B2
(en)
|
2001-12-24 |
2008-07-22 |
Astrazeneca Ab |
Substituted quinazoline derivatives as inhibitors of aurora kinases
|
|
JP4508650B2
(ja)
|
2002-01-29 |
2010-07-21 |
グラクソ グループ リミテッド |
アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物
|
|
AR038240A1
(es)
|
2002-01-29 |
2005-01-05 |
Glaxo Group Ltd |
Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
|
|
WO2003064413A1
(en)
|
2002-02-01 |
2003-08-07 |
Astrazeneca Ab |
Quinazoline compounds
|
|
DE10204462A1
(de)
|
2002-02-05 |
2003-08-07 |
Boehringer Ingelheim Pharma |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
|
TW200813014A
(en)
|
2002-03-28 |
2008-03-16 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
DE10217689A1
(de)
|
2002-04-19 |
2003-11-13 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
|
JPWO2003093238A1
(ja)
|
2002-05-01 |
2005-09-08 |
麒麟麦酒株式会社 |
マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
ES2400339T3
(es)
|
2002-07-15 |
2013-04-09 |
Symphony Evolution, Inc. |
Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
|
|
GB0219746D0
(en)
|
2002-08-23 |
2002-10-02 |
Inst Of Ex Botany Ascr |
Azapurine derivatives
|
|
EP1548008A4
(en)
|
2002-08-23 |
2008-08-06 |
Kirin Pharma Kk |
COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
|
|
US7419984B2
(en)
|
2002-10-17 |
2008-09-02 |
Cell Therapeutics, Inc. |
Pyrimidines and uses thereof
|
|
JP3763414B2
(ja)
|
2002-10-21 |
2006-04-05 |
麒麟麦酒株式会社 |
Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
|
|
AU2003280599A1
(en)
|
2002-10-29 |
2004-05-25 |
Kirin Beer Kabushiki Kaisha |
QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
|
|
KR101089462B1
(ko)
|
2002-11-04 |
2011-12-07 |
아스트라제네카 아베 |
Ｓｒｃ 티로신 키나제 억제제로서의 퀴나졸린 유도체
|
|
CA2509233A1
(en)
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
BR0317433A
(pt)
|
2002-12-18 |
2005-11-16 |
Pfizer Prod Inc |
Derivados bicìclicos para o tratamento do crescimento celular anormal
|
|
WO2004058267A1
(en)
|
2002-12-23 |
2004-07-15 |
Ariad Pharmaceuticals, Inc. |
Heterocycles and uses thereof
|
|
WO2004060373A1
(ja)
|
2002-12-27 |
2004-07-22 |
Santen Pharmaceutical Co., Ltd. |
滲出型加齢黄斑変性治療剤
|
|
US7662783B2
(en)
*
|
2003-02-20 |
2010-02-16 |
New York University |
CLK-peptide and SLK-peptide
|
|
US8176532B1
(en)
|
2003-03-17 |
2012-05-08 |
Sprint Communications Company L.P. |
Secure access point for scada devices
|
|
KR100559180B1
(ko)
|
2003-05-20 |
2006-03-14 |
김민서 |
조건부 거래에 따른 전자결제 방법 및 전자결제 서버
|
|
WO2005003140A1
(en)
|
2003-07-02 |
2005-01-13 |
Pharmacia & Upjohn Company Llc |
4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
|
|
EP1641759B1
(en)
|
2003-07-07 |
2014-03-12 |
Merck Patent GmbH |
Malonamide derivatives
|
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
AU2004288709B2
(en)
|
2003-11-07 |
2011-01-06 |
Novartis Vaccines And Diagnostics, Inc. |
Methods for synthesizing quinolinone compounds
|
|
WO2005073224A2
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
EP1773826A4
(en)
|
2004-07-02 |
2009-06-03 |
Exelixis Inc |
MODULATORS OF C-MET AND THEIR METHOD OF USE
|
|
JP2008505907A
(ja)
*
|
2004-07-06 |
2008-02-28 |
アンジオン バイオメディカ コーポレイション |
癌治療を目的として肝細胞増殖因子およびｃ−ｍｅｔ活性を調整するキナゾリンモジュレーター
|
|
US20080161305A1
(en)
|
2005-04-06 |
2008-07-03 |
Exelixis, Inc. |
C-Met Modulators and Methods of Use
|
|
WO2007062135A2
(en)
|
2005-11-23 |
2007-05-31 |
Junji Shiraishi |
Computer-aided method for detection of interval changes in successive whole-body bone scans and related computer program product and system
|
|
EP1963329B1
(en)
*
|
2005-11-30 |
2013-01-23 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of c-met and uses thereof
|
|
CA2645137A1
(en)
|
2006-03-07 |
2007-09-13 |
James F. Blake |
Heterobicyclic pyrazole compounds and methods of use
|
|
BRPI0709917A2
(pt)
*
|
2006-03-30 |
2011-07-05 |
Novartis Ag |
composições e métodos de uso para anticorpos de c-met
|
|
US20080004273A1
(en)
|
2006-05-30 |
2008-01-03 |
Stephane Raeppel |
Inhibitors of protein tyrosine kinase activity
|
|
US8217177B2
(en)
*
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
EP2062886B1
(en)
|
2006-08-23 |
2011-11-30 |
Eisai R&D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
|
CN111643496A
(zh)
*
|
2006-12-14 |
2020-09-11 |
埃克塞利希斯股份有限公司 |
使用mek抑制剂的方法
|
|
JPWO2009096435A1
(ja)
*
|
2008-01-29 |
2011-05-26 |
武田薬品工業株式会社 |
縮合複素環誘導体およびその用途
|
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
|
WO2009136663A1
(en)
*
|
2008-05-08 |
2009-11-12 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic derivatives and use thereof
|
|
UY32142A
(es)
|
2008-09-26 |
2010-05-31 |
Smithkline Beckman Corp |
Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
|
|
MX2011003363A
(es)
|
2008-10-01 |
2011-04-27 |
Ludwig Inst Cancer Res |
Metodos para el tratamiento de cancer.
|
|
WO2010056960A1
(en)
|
2008-11-13 |
2010-05-20 |
Exelixis Inc. |
Methods of preparing quinoline derivatives
|
|
JP2012511017A
(ja)
|
2008-12-04 |
2012-05-17 |
エグゼリクシス， インコーポレイテッド |
キノリン誘導体の調製方法
|
|
TW202112751A
(zh)
*
|
2009-01-16 |
2021-04-01 |
美商艾克塞里克斯公司 |
包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
|
|
WO2011009095A1
(en)
|
2009-07-17 |
2011-01-20 |
Exelixis, Inc. |
Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
US20110059081A1
(en)
|
2009-09-09 |
2011-03-10 |
Quintiles Transnational Corp. |
Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
|
|
KR20130038206A
(ko)
|
2010-03-12 |
2013-04-17 |
엑셀리시스, 인코포레이티드 |
Ｎ-〔3-플루오로-4-(｛6-（메틸옥시）-7-〔（3-모폴린-4-일프로필）옥시〕-퀴놀린-4-일｝옥시）페닐〕-ｎ’-（4-플루오로페닐）사이클로프로판-1,1-디카복사미드의 수화된 결정형 형태
|
|
US20120070368A1
(en)
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
|
US20140186407A9
(en)
|
2010-07-16 |
2014-07-03 |
Exelixis Inc. |
C-Met Modulator Pharmaceutical Compositions
|
|
EA030435B1
(ru)
|
2010-07-16 |
2018-08-31 |
Экселиксис, Инк. |
ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
|
|
EP2643001A4
(en)
|
2010-11-22 |
2014-02-19 |
Glaxosmithkline Ip Dev Ltd |
METHOD OF TREATING CANCER
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
CA2854336A1
(en)
|
2011-11-08 |
2013-05-16 |
Exelixis, Inc. |
Dual inhibitor of met and vegf for treating cancer
|
|
HK1207587A1
(en)
|
2012-05-02 |
2016-02-05 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
CN114129566A
(zh)
|
2012-09-07 |
2022-03-04 |
埃克塞里艾克西斯公司 |
用于治疗肺腺癌的met、vegfr和ret的抑制剂
|
|
MX2015014046A
(es)
|
2013-04-04 |
2016-05-16 |
Exelixis Inc |
Combinaciones de farmacos para tratar cancer.
|
|
EP3119476A1
(en)
|
2014-03-17 |
2017-01-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
MA40457A
(fr)
|
2014-08-05 |
2017-06-14 |
Exelixis Inc |
Combinaison de médicaments pour traiter le myélome multiple
|